Traws Pharma, Inc. (TRAW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Traws Pharma, Inc., a Delaware corporation, on December 16, 2025, covering events occurring on December 12, 2025. The Company is an emerging growth company with common stock trading on The Nasdaq Stock Market LLC under the symbol "TRAW."
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On December 12, 2025, the Compensation Committee approved grants of stock options and restricted stock units (RSUs) to five executive officers under the Amended and Restated 2021 Incentive Compensation Plan. The grants are subject to continued service and vest in full on the first anniversary of the grant date.
| Executive Officer | Options Granted | RSUs Granted |
|---|---|---|
| Iain Dukes (CEO) | 147,771 | 36,943 |
| Charles Parker (CFO) | 61,571 | 15,393 |
| C. David Pauza (CSO, Virology) | 73,886 | 18,471 |
| Robert Redfield (CMO) | 65,676 | 16,419 |
| Nikolay Savchuk (COO) | 65,676 | 16,419 |
Option Terms: The exercise price is set at $2.33 per share, reflecting the closing stock price on December 12, 2025. The options have a ten-year term.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard vesting conditions tied to continued employment.
Key Facts for Investor Verification
- Stock Price Impact: Verify the current market price relative to the $2.33 exercise price to assess the intrinsic value of the granted options.
- Dilution Potential: Calculate the total number of shares underlying the grants (414,580 options and 103,645 RSUs) against the current share count to estimate potential dilution upon vesting and exercise.
- Retention Risk: Note that all grants vest in full on the first anniversary; verify if this aligns with the Company's strategic timeline for key milestones.
- Plan Capacity: Confirm the remaining share availability under the 2021 Incentive Compensation Plan to assess future grant capacity.